 Kamada Ltd NASDAQ: KMDA has acquired four FDA-approved plasma-derived hyperimmune commercial products from Saol Therapeutics. Kamada will pay Saol a 95 million upfront payment and an additional 50 million in sales milestones during 2022-2034. 